The Royal Australian and New Zealand College of Psychiatrists (RANZCP) supports the availability of vaping devices with nicotine as consumer products for smokers who are unable or unwilling to quit.
People living with mental illness are more likely to smoke tobacco and smoke more heavily than the general population. This is the leading cause of the poorer health and mortality outcomes suffered by this group.
Tobacco harm reduction is an essential component of any framework that aims to improve health outcomes for people who smoke tobacco.
Tobacco smokers should have ready access to a broad range of harm reduction and smoking cessation tools.
Smoking cessation rates are lower for people living with mental illness. Tobacco harm reduction strategies may therefore provide particular benefits for this population group.
E-cigarettes and vaporisers may provide a less harmful way to deliver nicotine to those who are unable or unwilling to stop smoking tobacco. However, there are no long-term studies recording the magnitude of the effects of long-term vapour inhalation on people’s health.
Further research is required to ascertain the effectiveness of e-cigarettes and vaporisers as tools for smoking cessation and whether they may provide a novel route into smoking initiation. This does not justify withholding what is, on the current evidence, a lower-risk product from existing smokers while such data is collected
See The Royal Australian and New Zealand College of Psychiatrists (RANZCP) latest Position Statement here https://www.ranzcp.org/News-policy/Policy-submissions-reports/Document-library/E-cigarettes-and-vaporisers